Mda-mb-231-luc-d3h2ln
Mda-mb-231-luc-d3h2ln - Related Videos
09:22
Invasive Behavior of Human Breast Cancer Cells in Embryonic Zebrafish
0 Views •
Cited by 44 •
2017
Here, we describe xenograft zebrafish models using two different injection sites, i.e., perivitelline space and duct of Cuvier, to investigate the invasive behavior and to assess the intravasation and extravasation potential of human breast cancer cells, respectively.
07:31
Testing the Vascular Invasive Ability of Cancer Cells in Zebrafish (Danio Rerio)
0 Views •
Cited by 19 •
2016
This method utilizes zebrafish embryos to efficiently test the vascular invasive ability of cancer cells. Fluorescent cancer cells are injected into the precardiac sinus or yolk sac of developing embryos. Cancer cell vascular invasion and extravasation is assessed via fluorescence microscopy of the tail region 24 to 96 hr later.
03:33
Generating Conditional Knockdown Cells Using a Tetracycline-Responsive Lentiviral shRNA Expression System
0 Views •
2026
Source: Kubala, M. H. & DeClerck, Y. A. Conditional Knockdown of Gene Expression in Cancer Cell Lines to Study the Recruitment of Monocytes/Macrophages to the Tumor Microenvironment. J. Vis. Exp. (2017)This video demonstrates the generation of conditional knockdown cancer cell lines using a Tet-inducible lentiviral shRNA system. It outlines the steps for viral transduction, antibiotic selection, and doxycycline-induced gene silencing.
02:40
Detecting SMAD Pathway Activation Using Dual Adenovirus Transduction
0 Views •
2026
Source: Chen, H., et al. Live Cell Imaging of the TGF-β/Smad3 Signaling Pathway In Vitro and In Vivo Using an Adenovirus Reporter System. J. Vis. Exp. (2018).This video demonstrates a method to study SMAD pathway activation in breast cancer cells using dual adenoviral infection. One virus delivers a constitutively expressed GFP gene, while the other carries an RFP reporter under a SMAD-sensitive promoter. Upon TGF-beta stimulation, SMAD proteins are activated, forming a complex that induces RFP...
03:57
Preparation of Reporter-Expressing Cancer Cells for In Vivo Imaging
0 Views •
2026
Source: Chen, H. et. al. Live Cell Imaging of the TGF-β/Smad3 Signaling Pathway In Vitro and In Vivo Using an Adenovirus Reporter System. J. Vis. Exp. (2018)This video demonstrates the preparation of luciferase-expressing breast cancer cells using recombinant adenoviruses for in vivo imaging.
FAQs
The luciferase reporter converts the presence of luciferin, oxygen, and ATP into a light-producing reaction. Because ATP and oxygen are required, the signal can identify cells that remain biologically active rather than merely detecting a static marker. In MDA-mb-231-luc-D3H2LN experiments, bioluminescence provides a functional readout for locating and following tumor cells in living systems.
Each component is necessary for luciferase-driven light production, so the complete reaction determines whether tumor cells generate a detectable signal. This requirement ties the readout to viable cells and means that luciferase expression alone does not explain the measured bioluminescence. Interpreting results therefore requires considering the substrate and reaction conditions used during imaging.
Its relevance comes from combining a human breast cancer background with a luciferase-based method for monitoring tumor burden and metastatic colonization over time. This combination supports investigation of progression in a brain-metastasis research context while allowing researchers to assess how candidate treatments affect disease in living systems.
Researchers supply luciferin to a living system containing the cells and acquire light-based measurements, then repeat observations to follow changes in tumor burden or metastatic progression. This noninvasive format supports longitudinal assessment, allowing growth patterns and treatment-associated changes to be examined in the same living system rather than inferred from a single endpoint.
Changes in bioluminescent detection over time can be compared with tumor burden and metastatic colonization to evaluate whether a candidate therapeutic is associated with altered disease progression. The approach provides a dynamic outcome rather than only a final observation, helping researchers relate treatment to patterns of tumor growth or spread in the living model.
MDA-mb-231-luc-D3H2LN supports studies of disease mechanisms while providing a way to test candidate therapeutics in a breast cancer setting relevant to metastatic progression. Its noninvasive monitoring capability allows investigators to follow tumor-related changes over time, generating evidence about how disease develops and how interventions influence tumor burden or metastatic behavior.